18 research outputs found
T cell depleted hosts are uniquely susceptible to tolerance induced by non-professional APCs and mediated by IL-10 producing CD8+ T cells
n/
249: Prolonged Survival for Ultra High-Risk Pediatric Sarcoma Patients following Reduced-Intensity Allogeneic Stem Cell Transplantation (AlloSCT)
Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.
The first annual conference on immunotherapy in pediatric oncology was held in Bethesda, MD, from September 9 to 10, 2008 to discuss the state-of-the-art of immunotherapeutic strategies currently being explored in pediatric oncology. Major topics included targeting cell surface receptors, understanding and improving T-cell-based therapies, augmenting innate immune strategies, and enhancing graft-versus-leukemia for pediatric malignancies. As can be seen in the summaries of the individual presentations, significant progress has been made in developing preclinical models of pediatric tumors and a variety of novel immunobiologic therapies are approaching, or already in, the clinic. Although there is much excitement about the potential utility of these agents, a great deal of challenges lie ahead in improving the efficacy of each of these modalities and getting them to patients in a timely fashion. The resulting discussions will hopefully lead to new collaborations and insight for further translational and clinical studies